AU2021285997A1 - Live attenuated respiratory syncytial virus - Google Patents

Live attenuated respiratory syncytial virus Download PDF

Info

Publication number
AU2021285997A1
AU2021285997A1 AU2021285997A AU2021285997A AU2021285997A1 AU 2021285997 A1 AU2021285997 A1 AU 2021285997A1 AU 2021285997 A AU2021285997 A AU 2021285997A AU 2021285997 A AU2021285997 A AU 2021285997A AU 2021285997 A1 AU2021285997 A1 AU 2021285997A1
Authority
AU
Australia
Prior art keywords
rsv
seq
lid
recombinant
vims
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021285997A
Other languages
English (en)
Inventor
Ursula Buchholz
Peter Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2021285997A1 publication Critical patent/AU2021285997A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021285997A 2020-06-05 2021-06-04 Live attenuated respiratory syncytial virus Pending AU2021285997A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035617P 2020-06-05 2020-06-05
US63/035,617 2020-06-05
PCT/US2021/036030 WO2021248086A2 (en) 2020-06-05 2021-06-04 Live attenuated respiratory syncytial virus

Publications (1)

Publication Number Publication Date
AU2021285997A1 true AU2021285997A1 (en) 2023-01-19

Family

ID=76708442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021285997A Pending AU2021285997A1 (en) 2020-06-05 2021-06-04 Live attenuated respiratory syncytial virus

Country Status (10)

Country Link
US (1) US20230279362A1 (https=)
EP (1) EP4161567A2 (https=)
JP (1) JP2023529836A (https=)
KR (1) KR20230021115A (https=)
CN (1) CN116568323A (https=)
AU (1) AU2021285997A1 (https=)
BR (1) BR112022024539A2 (https=)
CA (1) CA3185143A1 (https=)
MX (1) MX2022015398A (https=)
WO (1) WO2021248086A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
CN1997559A (zh) * 2004-06-25 2007-07-11 西蒙·赫姆·延森 具有一体化提手的容器体
PT3511015T (pt) * 2012-04-13 2021-04-05 Us Health Vacina viva e atenuada e geneticamente estável contra o vírus sincicial respiratório e a sua produção
EP4190895A1 (en) * 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
DK3247388T3 (da) * 2015-01-20 2025-12-22 Us Health Rekombinant human/bovin parainfluenzavirus 3 (b/hpiv3), der udtrykker et kimærisk rsv/bpiv3 f-protein, og anvendelser deraf
KR102854980B1 (ko) * 2015-12-11 2025-09-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주

Also Published As

Publication number Publication date
EP4161567A2 (en) 2023-04-12
CN116568323A (zh) 2023-08-08
KR20230021115A (ko) 2023-02-13
BR112022024539A2 (pt) 2022-12-27
JP2023529836A (ja) 2023-07-12
WO2021248086A2 (en) 2021-12-09
CA3185143A1 (en) 2021-12-09
US20230279362A1 (en) 2023-09-07
MX2022015398A (es) 2023-04-05
WO2021248086A3 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
Graham Biological challenges and technological opportunities for respiratory syncytial virus vaccine development
US12054519B2 (en) Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
CA2828229C (en) Recombinant mumps virus vaccine
US11975063B2 (en) Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
CN118302191A (zh) 基于病毒载体的人偏肺病毒疫苗
US20240197861A1 (en) Recombinant chimeric bovine/human parainfluenza virus 3 expressing sars-cov-2 spike protein and its use
JP7357709B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
US11918638B2 (en) Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
KR20210005090A (ko) 키메라 벡터
US20230279362A1 (en) Live attenuated respiratory syncytial virus
US20060110740A1 (en) Use of sendai virus as a human parainfluenza vaccine
KR20010080863A (ko) 마진 바이러스 또는 인간 호흡기 합포체 바이러스서브그룹 비에서 감쇠 담당 돌연변이
JP2023003315A (ja) コロナウイルスワクチン
RU2773746C2 (ru) Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов
WO2026080706A1 (en) Recombinant chimeric bovine/human parainfluenza virus 3 expressing avian influenza virus proteins and use thereof